EP4727978A2 - Zusammensetzungen mit antimutanten kras-antikörpern und verfahren zur verwendung davon - Google Patents

Zusammensetzungen mit antimutanten kras-antikörpern und verfahren zur verwendung davon

Info

Publication number
EP4727978A2
EP4727978A2 EP24824327.1A EP24824327A EP4727978A2 EP 4727978 A2 EP4727978 A2 EP 4727978A2 EP 24824327 A EP24824327 A EP 24824327A EP 4727978 A2 EP4727978 A2 EP 4727978A2
Authority
EP
European Patent Office
Prior art keywords
seq
set forth
sequence set
cdr
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24824327.1A
Other languages
English (en)
French (fr)
Inventor
Jose CONEJO GARCIA
Carmen Anadon GALINDO
Subir Biswas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of EP4727978A2 publication Critical patent/EP4727978A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP24824327.1A 2023-06-15 2024-06-15 Zusammensetzungen mit antimutanten kras-antikörpern und verfahren zur verwendung davon Pending EP4727978A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508423P 2023-06-15 2023-06-15
PCT/US2024/034234 WO2024259398A2 (en) 2023-06-15 2024-06-15 Compositions comprising anti-mutant kras antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
EP4727978A2 true EP4727978A2 (de) 2026-04-22

Family

ID=93852710

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24824327.1A Pending EP4727978A2 (de) 2023-06-15 2024-06-15 Zusammensetzungen mit antimutanten kras-antikörpern und verfahren zur verwendung davon

Country Status (2)

Country Link
EP (1) EP4727978A2 (de)
WO (1) WO2024259398A2 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9878043B2 (en) * 2006-06-23 2018-01-30 Engeneic Molecular Delivery Pty Ltd Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
US20250122308A1 (en) * 2021-09-17 2025-04-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeting mutant kras with a mutation specific iga
WO2024036232A2 (en) * 2022-08-09 2024-02-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibodies and uses thereof

Also Published As

Publication number Publication date
WO2024259398A3 (en) 2025-04-24
WO2024259398A2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
US11407801B2 (en) SIRP-gamma polypeptide compositions and treatment of cancer
KR102902719B1 (ko) 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
US12527838B2 (en) Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel
AU2020374947B2 (en) Anti-CD47 and anti-CD20 based treatment of blood cancer
AU2019253681A1 (en) Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation
US11629190B2 (en) Canine antibody therapeutic for treating cancer
WO2016179472A2 (en) Modulation of natural killer cell tolerance
WO2024259371A2 (en) COMPOSITIONS FOR AND METHODS OF EXPANDING γδ T CELLS
US20260091125A1 (en) Multifunctional delivery system and uses thereof
WO2024259398A2 (en) Compositions comprising anti-mutant kras antibodies and methods of use thereof
JP2026501282A (ja) Ｐｄ－１軸結合アンタゴニストおよびｒｎａワクチンを用いて膵臓がんを処置する方法
WO2024036232A2 (en) Bispecific antibodies and uses thereof
WO2026085357A2 (en) Compositions comprising antibodies having pigr-binding peptides and methods of use thereof
US20250136689A1 (en) Compositions for and methods of treating hematological cancers
WO2025101911A1 (en) Compositions comprising selective cell in organ targeting and methods of using the same
WO2025090985A1 (en) Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof
WO2025235413A1 (en) Compositions targeting cancer antigens and methods of use thereof
WO2025049355A1 (en) Compositions comprising nanoparticles for targeted delivery and methods of using the same
HK40056906A (en) Sirp polypeptide compositions and methods of use
HK40121936A (zh) 用pd-1轴结合拮抗剂和rna疫苗治疗胰腺癌的方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260106

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR